24小时热门版块排行榜

>虫友互识 (1156)
>论坛更新日志 (311)
>导师招生 (205)
>论文道贺祈福 (175)
>高分子 (80)
>硕博家园 (45)
>休闲灌水 (33)
>招聘信息布告栏 (29)
>学术会议 (21)
>考博 (18)
>找工作 (18)
>论文投稿 (17)
>博后之家 (11)
>考研 (11)
>检索知识 (10)
>教师之家 (8)

返回列表

当前主题已经存档。

abcd888898

银虫 (正式写手)

应助: 0 (幼儿园)
金币: 646.8
散金: 11
帖子: 326
在线: 39.4小时
虫号: 417550
注册: 2007-07-01
性别: GG
专业: 药品注册

[交流] 【转帖】Novo Nordisk receives approval for Victoza® in Japan

Novo Nordisk receives approval for Victoza® in Japan (20 January 2010)
Read in PDF format

Novo Nordisk receives approval for Victoza® in Japan

Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Victoza® for the treatment of type 2 diabetes.

Victoza® is the brand name for liraglutide, the first Glucagon-Like Peptide-1 (GLP-1) analogue approved in Japan, developed for the treatment of type 2 diabetes. Victoza® is indicated as monotherapy or as an add-on to sulphonylurea (SU) in people with type 2 diabetes.

"The Japanese approval of Victoza® represents a major advancement in the treatment of type 2 diabetes and an important milestone for Novo Nordisk." says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "We are excited to pioneer the GLP-1 market in Japan, where we are convinced Victoza® will prove to be a valuable treatment option for people with type 2 diabetes. The clinical studies conducted in Japan showed Victoza® to provide superior glucose control with a low risk of hypoglycaemia."

Novo Nordisk expects to launch Victoza® in Japan in the first half of 2010 upon completion of price negotiations.

回复此楼